ClinicalTrials.gg
CompletedNCT01469013Updated Sep 20, 2019Results posted

Oral Baricitinib (LY3009104)Treatment in Japanese Participants With Active Rheumatoid Arthritis on Background Methotrexate Therapy

A Phase 2 interventional study of Placebo and Baricitinib in Arthritis, Rheumatoid, sponsored by Eli Lilly and Company. Completed at 14 sites in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-09-20.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
145
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing baricitinib in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, 1 of them phase 3. baricitinib · Arthritis, Rheumatoid.

Enrollment
13th of 23
145 · median 290
Started
2011
with 1 other
Phase 2
3 of 23
none open now
Registered
4th of 23
by date
Lead sponsor
11 of 23
Eli Lilly and Company

Among the 23 studies testing baricitinib in Arthritis, Rheumatoid, this one is the 13th largest by enrollment, is one of 2 that started in 2011, is one of 3 in phase 2, and was the 4th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 23 studies testing baricitinib in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About baricitinib

baricitinib: first FDA approval 2018 (OLUMIANT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing baricitinib in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This is a Phase 2b, outpatient, randomized, double-blinded (with a single-blind extension), placebo-controlled, dose-ranging, parallel-group study of baricitinib (LY3009104) in Japanese participants with active rheumatoid arthritis (RA) on background methotrexate (MTX) therapy. Baricitinib will be orally administered once a day with background methotrexate [6 to 16 milligrams (mg)/week] therapy for 12 weeks in the double-blind treatment period (1, 2, 4 or 8 mg/day, or placebo), and for 52 weeks in the single-blind extension period (4 or 8 mg/day).

03

Conditions studied

  • Arthritis, Rheumatoid
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ambulatory males or females between the ages of 20 and 75 years, inclusive, at time of study entry
  • Diagnosis of adult-onset RA (of at least 6 months duration but not longer than 15 years prior to screening) according to the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Responder Index classification criteria for RA
  • Have active RA defined as at least 6 swollen and at least 6 tender joints based on the 66/68 joint count
  • Regular use of MTX for at least 12 weeks, and treatment at a stable dose of 6 to 16 mg/week (2 or 3 times a week) for at least 8 weeks prior to the treatment period. The dose of MTX should remain stable throughout the study, but may be adjusted for safety reasons.
  • For participants receiving , they must be on a dose not to exceed 10 mg of prednisone daily (or equivalent) and have been on the same dosing regimen for at least 6 weeks prior to the treatment period
  • Have C-Reactive Protein (CRP) measurement > 0.5 milligrams/deciliter (mg/dL) or Erythrocyte Sedimentation Rate (ESR) > 28 millimeters/hour (mm/hr). The CRP and ESR may be repeated once during the screening period at the discretion of the investigator, and the repeat results may be accepted for study eligibility purposes

Exclusion criteria

Exclusion Criteria:

  • Use of nonsteroidal anti-inflammatories (NSAIDs) for less than 4 weeks prior to the treatment period. If on NSAIDs, must be on a stable dose of the drug for at least 4 weeks prior to the treatment period and must remain on a stable dose throughout the study
  • Received prior treatment with an oral Janus Kinase (JAK) inhibitor regardless of when they received it
  • Have a diagnosis of Felty's syndrome
  • Evidence of (HIV) infection and/or positive human HIV antibodies
  • Have virus (HCV; positive for anti-hepatitis C antibody with confirmed presence of HCV)
  • Positive for surface antigen (HBsAg+), OR negative for hepatitis B surface antigen (HBsAg-), but positive for hepatitis B core antibody (HBcAb+) and/or positive for hepatitis B surface antibody (HBsAb+) with positive Hepatitis B virus (HBV)-deoxyribonucleic acid (DNA) [≥2.1 Log copy/mL by Polymerase Chain Reaction (PCR) method] detected in the serum
  • Have a positive result of the QuantiFERON®-tuberculosis (TB) Gold test (QFT-G) or a purified protein derivative (PPD) test
  • Have estimated (GFR) from serum creatinine using the Modification of Diet in Renal Disease (MDRD) method of \<50 milliliter/minute (mL/min)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
145 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    2 placebo capsules administered orally once daily for 12 weeks. Participants who complete this treatment arm will be randomized in a 1:1 ratio to either the 4-mg baricitinib or 8-mg baricitinib arms. Participants rerandomized to 8-mg baricitinib arm at Week12 will switch to 4-mg baricitinib once a day after the approval of protocol amendment (d) and will receive that switched dose until Week 64. The dosage form changed from capsule in treatment period (up to Week 12) to tablet in extension period (Week 13 to 64) per protocol amendment (b).

    Drug: Placebo · Drug: Methotrexate

  • Experimental
    1-mg Baricitinib (LY3009104)

    1 x 1-mg baricitinib capsule + 1 identical placebo capsule, both administered orally once daily for 12 weeks. Participants who complete this treatment arm will be randomized in a 1:1 ratio to either the 4-mg baricitinib or 8-mg baricitinib arms. Participants rerandomized to 8-mg baricitinib arm at Week 12 will switch to 4-mg baricitinib once a day after the approval of protocol amendment (d) and will receive that switched dose until Week 64. The dosage form changed from capsule in treatment period (up to Week 12) to tablet in extension period (Week 13 to 64) per protocol amendment (b).

    Drug: Placebo · Drug: Baricitinib · Drug: Methotrexate

  • Experimental
    2-mg Baricitinib (LY3009104)

    2 x 1-mg baricitinib capsules administered orally once daily for 12 weeks. Participants who complete this treatment arm will be randomized in a 1:1 ratio to either the 4-mg baricitinib or 8-mg baricitinib arms. Participants rerandomized to 8-mg baricitinib arm at Week 12 will switch to 4-mg baricitinib once a day after the approval of protocol amendment (d) and will receive that switched dose until Week 64. The dosage form changed from capsule in treatment period (up to Week 12) to tablet in extension period (Week 13 to 64) per protocol amendment (b).

    Drug: Baricitinib · Drug: Methotrexate

  • Experimental
    4-mg Baricitinib (LY3009104)

    1 x 4-mg baricitinib capsule + 1 identical placebo capsule, both administered orally once daily for 12 weeks. Participants who complete this 12-week period will remain on this treatment regimen in tablet form.

    Drug: Placebo · Drug: Baricitinib · Drug: Methotrexate

  • Experimental
    8-mg Baricitinib (LY3009104)

    2 x 4-mg baricitinib capsules administered orally once daily for 12 weeks. Participants who complete this 12-week period will remain on this treatment regimen in tablet form. Participants taking 8-mg baricitinib tablet form will switch to 4-mg baricitinib once a day after the approval of protocol amendment (d) and will receive that switched dose until Week 64.

    Drug: Baricitinib · Drug: Methotrexate

Interventions

  • DrugPlacebo

    Also known as: Sugar pill

  • Also known as: JAK1/JAK2 inhibitor, JAK1 inhibitor, JAK2 inhibitor, NCB028050, LY3009104

  • Also known as: JAK1/JAK2 inhibitor, JAK1 inhibitor, JAK2 inhibitor, NCB028050, LY3009104

  • Also known as: JAK1/JAK2 inhibitor, JAK1 inhibitor, JAK2 inhibitor, NCB028050, LY3009104

  • Administered orally as background therapy

06

What researchers measure

Primary outcomes

  1. Percentage of Participants in the 4 mg and 8 mg Dose Groups Who Achieved an American College of Rheumatology 20 (ACR20) Responder Index Response Baseline Through Week 12 .

    ACR20 responders are participants with at least 20% improvement from baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: Health Assessment Questionnaire-Disability Index (HAQ-DI) which measured participants perceived degree of difficulty performing daily activities, C-reactive Protein (CRP) and erythrocyte sedimentation rate (ESR), Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS) , Patient's Global Assessment of Disease Activity-VAS (PtGADA-VAS), and Physician's Global Assessment of Disease Activity-VAS (PhGA-VAS). Missing values were imputed using Non-Responder Imputation (NRI), where non-responders were participants who discontinued the study prior to the completion of Part A. Percentage of participants achieving ACR20 response = (number of ACR20 responders) /(number of participants treated) \* 100.

    Time frame: 12 weeks

Secondary outcomes

  1. Percentage of Participants Who Achieved an ACR20 Response at 64 Weeks

    ACR20 responders are participants with at least 20% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI which measured participants perceived degree of difficulty performing daily activities, CRP and ESR, PAAP-VAS, PtGADA-VAS, or PhGA-VAS. Missing values were imputed using NRI, where non-responders were participants who discontinued the study prior to the completion of Part B. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants treated) \* 100.

    Time frame: Baseline up to 64 weeks

  2. Percentage of Participants Who Achieved an ACR70 Response at 12 Weeks (Part A)

    ACR70 responders were participants with at least 70% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, or PhGA-VAS. Missing values were imputed using NRI, where non-responders were participants who discontinued the study prior to the completion of Part A. Percentage of participants achieving ACR70 response=(number of ACR70 responders / number of participants treated) \* 100.

    Time frame: Baseline up to 12 weeks

  3. Percentage of Participants Who Achieved an ACR70 Response at 64 Weeks (Part B)

    ACR70 responders were participants with at least 70% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, or PhGA-VAS. Missing values were imputed using NRI, where non-responders were participants who discontinued the study prior to the completion of Part B. Percentage of participants achieving ACR70 response=(number of ACR70 responders) / (number of participants treated) \* 100.

    Time frame: Baseline up to 64 weeks

  4. Mean Change From Baseline to Week 12 in Disease Activity Score (DAS) Based on the 28 Diarthrodial Joint Count and CRP Level (DAS28-CRP)

    DAS modified included the DAS28 that consisted of a composite score of the following variables: tender joint count out of 28 (TJC28), swollen joint count out of 28 (SJC28), CRP \[milligrams per liter (mg/L)\], and PtGADA on a 0 to 100 millimeter (mm) VAS (0mm=no arthritis activity to 100 mm= extremely active arthritis). DAS28 calculated as: DAS28-CRP = 0.56(square root of TJC28)+0.28(square root of SJC28)+0.36\[ln(CRP +1)\]+0.014(VAS)+0.96. A decrease in DAS28-CRP indicated an improvement in participant's condition.

    Time frame: Baseline, 12 weeks

  5. Mean Change From Baseline to Week 64 in DAS Based on the 28 Diarthrodial Joint Count and CRP Level (DAS28-CRP)

    DAS modified included the 28 diarthroidal joint count (DAS28) that consisted of a composite score of the following variables: TJC28, SJC28, CRP (mg/L), and PtGADA on a 0 to 100 mm VAS (0mm=no arthritis activity to 100 mm= extremely active arthritis). DAS28 calculated as: DAS28-CRP = 0.56(square root of TJC28)+0.28(square root of SJC28)+0.36\[ln(CRP +1)\]+0.014(VAS)+0.96. A decrease in DAS28-CRP indicated an improvement in participant's condition.

    Time frame: Baseline, 64 weeks

  6. Percentage of Participants Who Achieved an European League Against Rheumatism Rating of 28-Joint Arthritic Condition (EULAR28) Response at 12 Weeks (Part A)

    EULAR Responder Index based on 28 joint counts categorizes clinical response based on improvement from baseline in DAS28-CRP. DAS28-CRP scores range from 1.0-9.4, where lower scores indicated less disease activity. High disease activity: DAS28-CRP \>5.1, low disease activity: DAS28-CRP ≤3.2, and remission: DAS28-CRP \<2.6. Participants are categorized as EULAR responders or non-responders based on improvement of DAS28-CRP scores from baseline. EULAR DAS28-CRP responder index defines a good (absolute: ≤3.2 and \>1.2 improvement from baseline), moderate (absolute: \>3.2 and ≤5.1 and \>0.6 and ≤1.2 improvement from baseline), or no response (absolute: \>5.1 and ≤0.6 improvement from baseline). Percentage of participants calculated as = (number of good +moderate responders) / (number of participants treated) \* 100.

    Time frame: Baseline up to 12 weeks

  7. Percentage of Participants Who Achieved an EULAR28 Response at 64 Weeks (Part B)

    EULAR Responder Index based on 28 joint counts categorizes clinical response based on improvement from baseline in DAS28-CRP. DAS28-CRP scores range from 1.0-9.4, where lower scores indicated less disease activity. High disease activity: DAS28-CRP \>5.1, low disease activity: DAS28-CRP \<3.2, and remission: DAS28-CRP \<2.6. Participants are categorized as EULAR responders or non-responders based on improvement of DAS28-CRP scores from baseline. EULAR DAS28-CRP Responder Index defines a good (absolute: ≤3.2 and \>1.2 improvement from baseline), moderate (absolute: \>3.2 and ≤5.1 and \>0.6 and ≤1.2 improvement from baseline), or no response (absolute: \>5.1 and ≤0.6 improvement from baseline). Percentage of participants calculated as = (number of good +moderate responders) / (number of participants treated) \* 100.

    Time frame: Baseline up to 64 weeks

  8. Mean Change in Simplified Disease Activity Index (SDAI) Responses up to 12 Weeks (Part A)

    The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, patient and physician global assessment of disease activity and CRP. The equation used to calculate the SDAI:SDAI=SJC28+TJC28+PtGADA-VAS+PhGA-VAS+CRP where PtGADA-VAS=PtGADA-VAS / 10 and PhGA-VAS=PhGA-VAS / 10, with lower values indicating fewer symptoms.

    Time frame: Baseline up to 12 weeks

  9. Mean Change in SDAI Responses up to 64 Weeks (Part B)

    The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, PtGADA, PhGA, and CRP. The equation used to calculate the SDAI: SDAI=SJC28+TJC28+PtGADA-VAS+PhGA-VAS+CRP where PtGADA-VAS=PtGADA -VAS/ 10 and PhGA-VAS=PhGA-VAS/ 10, with lower values indicating fewer symptoms.

    Time frame: Baseline, 64 weeks

  10. Mean Change in Health Assessment Questionnaire - Disability Index (HAQ-DI) Responses up to 12 Weeks (Part A)

    HAQ-DI was a participant-reported questionnaire that consisted of 24 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the week using response categories: without any difficulty (0), with some difficulty (1), with much difficulty (2), and unable to do (3). The highest score for any question in a category was the score of that category unless special aids or devices or help from another person was required. Answers for at least 6 of the 8 domains were required. Otherwise, HAQ-DI score was considered missing. The HAQ-DI score was the sum of the category scores divided by the number of categories scored, with a possible scores range from 0 to 3, 0 being without any difficulty and 3 being unable to do.

    Time frame: Baseline, 12 weeks

  11. Mean Change in HAQ-DI Responses up to 64 Weeks (Part B)

    HAQ-DI was a participant-reported questionnaire that consisted of 24 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the week using response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). The highest score for any question in a category was the score of that category unless special aids or devices or help from another person was required. Answers for at least 6 of the 8 domains were required. Otherwise, HAQ-DI score was considered missing. The HAQ-DI score was the sum of the category scores divided by the number of categories scored, with a possible scores range from 0 to 3, 0 being without any difficulty and 3 being unable to do.

    Time frame: Baseline, 64 weeks

  12. Mean Value of ACR-N Response (Part A)

    The ACR-N Response Index is a continuous measure of clinical, laboratory, and functional measures in RA to characterize the percentage of improvement from baseline in RA disease activity. This index is defined as the lowest of either: a) percent change in TJC, b) percent change in SJC, or c) median percent change of the remaining 5 ACR core criteria (HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, or PhGA-VAS). A participant with an ACR-N of "X" has improvement of at least "X%" in tender and swollen joints and a median improvement of at least "X%" in the 5 remaining ACR core criteria. Since ACR-N is a continuous measure, the mean values are reported instead of the originally registered percentage of participants.

    Time frame: Baseline up to 12 weeks

  13. Mean Value of ACR-N Response (Part B)

    The ACR-N Response Index is a continuous measure of clinical, laboratory, and functional measures in RA to characterize the percentage of improvement from baseline in RA disease activity. This index is defined as the lowest of either: a) percent change in TJC, b) percent change in SJC, or c) median percent change of the remaining 5 ACR core criteria (HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, or PhGA-VAS). A participant with an ACR-N of "X" has improvement of at least "X%" in tender and swollen joints and a median improvement of at least "X%" in the 5 remaining ACR core criteria. Since ACR-N is a continuous measure, the mean values are reported instead of the originally registered percentage of participants.

    Time frame: Baseline up to 64 weeks

  14. Percentage of Participants Who Achieved a DAS28 Remission at 12 Weeks (Part A)

    DAS modified included the DAS28 that consisted of a composite score of the following variables: TJC28, SJC28, CRP (mg/L), and PtGADA on a 0 to 100 mm VAS: 0 mm (no arthritis activity) to 100 mm (extremely active arthritis). DAS28 calculated as: DAS28-CRP = 0.56(square root of TJC28)+0.28(square root of SJC28)+0.36\[ln(CRP +1)\]+0.014(VAS)+0.96. For remission, DAS28 is \<2.6. Percentage of participants = (number of participants with DAS28 remission) / (number of participants treated) \* 100.

    Time frame: Baseline up to 12 weeks

  15. Percentage of Participants Who Achieved a DAS28 Remission at 64 Weeks (Part B)

    DAS modified included the DAS28 that consisted of a composite score of the following variables: TJC28, SJC28, CRP (mg/L), and PtGADA-VAS on a 0 to 100 mm VAS: 0 mm (no arthritis activity) to 100 mm (extremely active arthritis). DAS28 calculated as: DAS28-CRP = 0.56(sqrt of TJC28)+0.28(sqrt of SJC28)+0.36\[ln(CRP +1)\]+0.014(VAS)+0.96. For remission, DAS28 is \<2.6. Percentage of participants = (number of participants with DAS 28 remission) / (number of participants treated) \* 100.

    Time frame: Baseline up to 64 weeks

  16. Percentage of Participants Who Achieved an SDAI Remission at 12 Weeks (Part A)

    The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, PtGADA, PhGA and CRP. The equation used to calculate the SDAI: SDAI=SJC28+TJC28+PtGADA-VAS+PhGA-VAS+CRP where PtGADA-VAS=PtGADA -VAS/ 10 and PhGA-VAS=PhGA-VAS / 10. Definition of remission is SDAI ≤ 3.3. Percentage of participants = (number of responders) / (number of participants treated) \* 100

    Time frame: Baseline up to 12 weeks

  17. Percentage of Participants Who Achieved an SDAI Remission at 64 Weeks (Part B)

    The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, PtGADA, PhGA, and CRP. The equation used to calculate the SDAI: SDAI=SJC28+TJC28+PtGADA-VAS+PhGA-VAS+CRP where PtGADA-VAS=PtGADA-VAS / 10 and PhGA-VAS=PhGA-VAS / 10. Definition of remission is SDAI ≤ 3.3. Percentage of participants = (number of responders) / (number of participants treated) \* 100

    Time frame: Baseline up to 64 weeks

  18. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve at a Dosing Interval at Steady State (AUCtau,ss) of LY3009104

    Steady state is achieved when the rate of drug input is equal to the rate of drug elimination. The AUC(tau,ss) at 1 dosing interval is the average concentration of the drug at steady state multiplied by the time of the dosing interval.

    Time frame: Weeks (Wks) 0, 8, 12, or 20: Predose, 15 to 30 minutes and 1 to 3 hours postdose; Wks 2 or 4 and 15 or 16: Predose; Wks 28, 40, 52, or 64: random single sample.

  19. PK: Maximum Concentration at Steady State of Dosing (Cmax,ss) of LY3009104

    Time frame: Wks 0, 8, 12, or 20: Predose, 15 to 30 minutes and 1 to 3 hours postdose; Wks 2 or 4 and 15 or 16: Predose; Wks 28, 40, 52, or 64: random single sample.

07

Results

Posted Nov 1, 2018

Participant flow

Part A (Treatment Period)
Participant flow — Part A (Treatment Period)
MilestonePart A: 1 mg Baricitinib (LY3009104)Part A: 2 mg Baricitinib (LY3009104)Part A: 4 mg Baricitinib (LY3009104)Part A: 8 mg Baricitinib (LY3009104)Part A: PlaceboPart:1 mg Baricitinib(LY3009104) / 4 mg Baricitinib(LY3009104)Part B: 2 mg Baricitinib (LY3009104) / 4 mg Baricitinib (LY30Part B: 4 mg Baricitinib (LY3009104) / 4 mg Baricitinib (LY30Part B: Placebo /4 mg Baricitinib (LY3009104)Part B: 1 mg Baricitinib (LY3009104) / 8 mg Baricitinib (LY30Part B: 2 mg Baricitinib (LY3009104) / 8 mg Baricitinib (LY300Part B: 8 mg Baricitinib (LY3009104) / 8 mg Baricitinib (LY30Part B: Placebo / 8 mg Baricitinib (LY3009104)
Started242424244900000000
Received at least 1 dose of study drug242424244900000000
Completed232423244800000000
Not completed1010100000000
Withdrew: Adverse event1000100000000
Withdrew: Withdrawal by subject0010000000000
Part B (Extension Period)
Participant flow — Part B (Extension Period)
MilestonePart A: 1 mg Baricitinib (LY3009104)Part A: 2 mg Baricitinib (LY3009104)Part A: 4 mg Baricitinib (LY3009104)Part A: 8 mg Baricitinib (LY3009104)Part A: PlaceboPart:1 mg Baricitinib(LY3009104) / 4 mg Baricitinib(LY3009104)Part B: 2 mg Baricitinib (LY3009104) / 4 mg Baricitinib (LY30Part B: 4 mg Baricitinib (LY3009104) / 4 mg Baricitinib (LY30Part B: Placebo /4 mg Baricitinib (LY3009104)Part B: 1 mg Baricitinib (LY3009104) / 8 mg Baricitinib (LY30Part B: 2 mg Baricitinib (LY3009104) / 8 mg Baricitinib (LY300Part B: 8 mg Baricitinib (LY3009104) / 8 mg Baricitinib (LY30Part B: Placebo / 8 mg Baricitinib (LY3009104)
Started000001212232411122424
Received at least 1 dose of study drug000001212232411122423
Completed0000010718208101818
Not completed0000025543266
Withdrew: Adverse event0000025533163
Withdrew: Withdrawal by subject0000000010103

Outcome measures

PrimaryPercentage of Participants in the 4 mg and 8 mg Dose Groups Who Achieved an American College of Rheumatology 20 (ACR20) Responder Index Response Baseline Through Week 12 .

ACR20 responders are participants with at least 20% improvement from baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: Health Assessment Questionnaire-Disability Index (HAQ-DI) which measured participants perceived degree of difficulty performing daily activities, C-reactive Protein (CRP) and erythrocyte sedimentation rate (ESR), Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS) , Patient's Global Assessment of Disease Activity-VAS (PtGADA-VAS), and Physician's Global Assessment of Disease Activity-VAS (PhGA-VAS). Missing values were imputed using Non-Responder Imputation (NRI), where non-responders were participants who discontinued the study prior to the completion of Part A. Percentage of participants achieving ACR20 response = (number of ACR20 responders) /(number of participants treated) \* 100.

Time frame:
12 weeks
Reported as:
Number · percentage of participants
Percentage of Participants in the 4 mg and 8 mg Dose Groups Who Achieved an American College of Rheumatology 20 (ACR20) Responder Index Response Baseline Through Week 12 .
percentage of participantsPart A: Combined 4 mg and 8 mg Baricitinib (LY3009104)Part A: Placebo
Percentage of Participants in the 4 mg and 8 mg Dose Groups Who Achieved an American College of Rheumatology 20 (ACR20) Responder Index Response Baseline Through Week 12 .7731
Statistical analysis
  • Part A: Combined 4 mg and 8 mg Baricitinib (LY3009104) vs Part A: Placebo · Regression, Logistic · p = <0.001
SecondaryPercentage of Participants Who Achieved an ACR20 Response at 64 Weeks

ACR20 responders are participants with at least 20% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI which measured participants perceived degree of difficulty performing daily activities, CRP and ESR, PAAP-VAS, PtGADA-VAS, or PhGA-VAS. Missing values were imputed using NRI, where non-responders were participants who discontinued the study prior to the completion of Part B. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants treated) \* 100.

Time frame:
Baseline up to 64 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an ACR20 Response at 64 Weeks
percentage of participantsCombined 4 mg Baricitinib (LY3009104) (Part B)Combined 8 mg Baricitinib (LY3009104) (Part B)
Percentage of Participants Who Achieved an ACR20 Response at 64 Weeks6673
SecondaryPercentage of Participants Who Achieved an ACR70 Response at 12 Weeks (Part A)

ACR70 responders were participants with at least 70% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, or PhGA-VAS. Missing values were imputed using NRI, where non-responders were participants who discontinued the study prior to the completion of Part A. Percentage of participants achieving ACR70 response=(number of ACR70 responders / number of participants treated) \* 100.

Time frame:
Baseline up to 12 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an ACR70 Response at 12 Weeks (Part A)
percentage of participants1 mg Baricitinib (LY3009104)2 mg Baricitinib (LY3009104)4 mg Baricitinib (LY3009104)8 mg Baricitinib (LY3009104)Placebo
Percentage of Participants Who Achieved an ACR70 Response at 12 Weeks (Part A)132929210
Statistical analysis
  • 1 mg Baricitinib (LY3009104) vs 2 mg Baricitinib (LY3009104) vs 4 mg Baricitinib (LY3009104) vs 8 mg Baricitinib (LY3009104) vs Placebo · Cochran-Armitage trend test · p = 0.009
SecondaryPercentage of Participants Who Achieved an ACR70 Response at 64 Weeks (Part B)

ACR70 responders were participants with at least 70% improvement from baseline for TJC, SJC, and at least 3 of the 5 remaining core set measures: HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, or PhGA-VAS. Missing values were imputed using NRI, where non-responders were participants who discontinued the study prior to the completion of Part B. Percentage of participants achieving ACR70 response=(number of ACR70 responders) / (number of participants treated) \* 100.

Time frame:
Baseline up to 64 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an ACR70 Response at 64 Weeks (Part B)
percentage of participantsCombined 4 mg Baricitinib (LY3009104)Combined 8 mg Baricitinib (LY3009104)
Percentage of Participants Who Achieved an ACR70 Response at 64 Weeks (Part B)3734
SecondaryMean Change From Baseline to Week 12 in Disease Activity Score (DAS) Based on the 28 Diarthrodial Joint Count and CRP Level (DAS28-CRP)

DAS modified included the DAS28 that consisted of a composite score of the following variables: tender joint count out of 28 (TJC28), swollen joint count out of 28 (SJC28), CRP \[milligrams per liter (mg/L)\], and PtGADA on a 0 to 100 millimeter (mm) VAS (0mm=no arthritis activity to 100 mm= extremely active arthritis). DAS28 calculated as: DAS28-CRP = 0.56(square root of TJC28)+0.28(square root of SJC28)+0.36\[ln(CRP +1)\]+0.014(VAS)+0.96. A decrease in DAS28-CRP indicated an improvement in participant's condition.

Time frame:
Baseline, 12 weeks
Reported as:
Mean · units on a scale
Mean Change From Baseline to Week 12 in Disease Activity Score (DAS) Based on the 28 Diarthrodial Joint Count and CRP Level (DAS28-CRP)
units on a scale1 mg Baricitinib (LY3009104)2 mg Baricitinib (LY3009104)4 mg Baricitinib (LY3009104)8 mg Baricitinib (LY3009104)Placebo
Mean Change From Baseline to Week 12 in Disease Activity Score (DAS) Based on the 28 Diarthrodial Joint Count and CRP Level (DAS28-CRP)-1.52 ± 0.970-2.02 ± 1.072-2.09 ± 1.105-1.96 ± 0.947-0.60 ± 1.204
SecondaryMean Change From Baseline to Week 64 in DAS Based on the 28 Diarthrodial Joint Count and CRP Level (DAS28-CRP)

DAS modified included the 28 diarthroidal joint count (DAS28) that consisted of a composite score of the following variables: TJC28, SJC28, CRP (mg/L), and PtGADA on a 0 to 100 mm VAS (0mm=no arthritis activity to 100 mm= extremely active arthritis). DAS28 calculated as: DAS28-CRP = 0.56(square root of TJC28)+0.28(square root of SJC28)+0.36\[ln(CRP +1)\]+0.014(VAS)+0.96. A decrease in DAS28-CRP indicated an improvement in participant's condition.

Time frame:
Baseline, 64 weeks
Reported as:
Mean · units on a scale
Mean Change From Baseline to Week 64 in DAS Based on the 28 Diarthrodial Joint Count and CRP Level (DAS28-CRP)
units on a scaleCombined 4 mg Baricitinib (LY3009104)Combined 8 mg Baricitinib (LY3009104)
Mean Change From Baseline to Week 64 in DAS Based on the 28 Diarthrodial Joint Count and CRP Level (DAS28-CRP)-2.44 ± 1.152-2.48 ± 1.109
SecondaryPercentage of Participants Who Achieved an European League Against Rheumatism Rating of 28-Joint Arthritic Condition (EULAR28) Response at 12 Weeks (Part A)

EULAR Responder Index based on 28 joint counts categorizes clinical response based on improvement from baseline in DAS28-CRP. DAS28-CRP scores range from 1.0-9.4, where lower scores indicated less disease activity. High disease activity: DAS28-CRP \>5.1, low disease activity: DAS28-CRP ≤3.2, and remission: DAS28-CRP \<2.6. Participants are categorized as EULAR responders or non-responders based on improvement of DAS28-CRP scores from baseline. EULAR DAS28-CRP responder index defines a good (absolute: ≤3.2 and \>1.2 improvement from baseline), moderate (absolute: \>3.2 and ≤5.1 and \>0.6 and ≤1.2 improvement from baseline), or no response (absolute: \>5.1 and ≤0.6 improvement from baseline). Percentage of participants calculated as = (number of good +moderate responders) / (number of participants treated) \* 100.

Time frame:
Baseline up to 12 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an European League Against Rheumatism Rating of 28-Joint Arthritic Condition (EULAR28) Response at 12 Weeks (Part A)
percentage of participants1 mg Baricitinib (LY3009104)2 mg Baricitinib (LY3009104)4 mg Baricitinib (LY3009104)8 mg Baricitinib (LY3009104)Placebo
Percentage of Participants Who Achieved an European League Against Rheumatism Rating of 28-Joint Arthritic Condition (EULAR28) Response at 12 Weeks (Part A)8388929247
SecondaryPercentage of Participants Who Achieved an EULAR28 Response at 64 Weeks (Part B)

EULAR Responder Index based on 28 joint counts categorizes clinical response based on improvement from baseline in DAS28-CRP. DAS28-CRP scores range from 1.0-9.4, where lower scores indicated less disease activity. High disease activity: DAS28-CRP \>5.1, low disease activity: DAS28-CRP \<3.2, and remission: DAS28-CRP \<2.6. Participants are categorized as EULAR responders or non-responders based on improvement of DAS28-CRP scores from baseline. EULAR DAS28-CRP Responder Index defines a good (absolute: ≤3.2 and \>1.2 improvement from baseline), moderate (absolute: \>3.2 and ≤5.1 and \>0.6 and ≤1.2 improvement from baseline), or no response (absolute: \>5.1 and ≤0.6 improvement from baseline). Percentage of participants calculated as = (number of good +moderate responders) / (number of participants treated) \* 100.

Time frame:
Baseline up to 64 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an EULAR28 Response at 64 Weeks (Part B)
percentage of participantsCombined 4 mg Baricitinib (LY3009104)Combined 8 mg Baricitinib (LY3009104)
Percentage of Participants Who Achieved an EULAR28 Response at 64 Weeks (Part B)9494
SecondaryMean Change in Simplified Disease Activity Index (SDAI) Responses up to 12 Weeks (Part A)

The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, patient and physician global assessment of disease activity and CRP. The equation used to calculate the SDAI:SDAI=SJC28+TJC28+PtGADA-VAS+PhGA-VAS+CRP where PtGADA-VAS=PtGADA-VAS / 10 and PhGA-VAS=PhGA-VAS / 10, with lower values indicating fewer symptoms.

Time frame:
Baseline up to 12 weeks
Reported as:
Mean · units on a scale
Mean Change in Simplified Disease Activity Index (SDAI) Responses up to 12 Weeks (Part A)
units on a scale1 mg Baricitinib (LY3009104)2 mg Baricitinib (LY3009104)4 mg Baricitinib (LY3009104)8 mg Baricitinib (LY3009104)Placebo
Mean Change in Simplified Disease Activity Index (SDAI) Responses up to 12 Weeks (Part A)-13.11 ± 8.918-16.85 ± 9.517-18.17 ± 9.202-18.02 ± 8.293-4.54 ± 13.113
SecondaryMean Change in SDAI Responses up to 64 Weeks (Part B)

The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, PtGADA, PhGA, and CRP. The equation used to calculate the SDAI: SDAI=SJC28+TJC28+PtGADA-VAS+PhGA-VAS+CRP where PtGADA-VAS=PtGADA -VAS/ 10 and PhGA-VAS=PhGA-VAS/ 10, with lower values indicating fewer symptoms.

Time frame:
Baseline, 64 weeks
Reported as:
Mean · units on a scale
Mean Change in SDAI Responses up to 64 Weeks (Part B)
units on a scaleCombined 4 mg Baricitinib (LY3009104)Combined 8 mg Baricitinib (LY3009104)
Mean Change in SDAI Responses up to 64 Weeks (Part B)-20.42 ± 9.671-21.33 ± 10.318
SecondaryMean Change in Health Assessment Questionnaire - Disability Index (HAQ-DI) Responses up to 12 Weeks (Part A)

HAQ-DI was a participant-reported questionnaire that consisted of 24 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the week using response categories: without any difficulty (0), with some difficulty (1), with much difficulty (2), and unable to do (3). The highest score for any question in a category was the score of that category unless special aids or devices or help from another person was required. Answers for at least 6 of the 8 domains were required. Otherwise, HAQ-DI score was considered missing. The HAQ-DI score was the sum of the category scores divided by the number of categories scored, with a possible scores range from 0 to 3, 0 being without any difficulty and 3 being unable to do.

Time frame:
Baseline, 12 weeks
Reported as:
Mean · units on a scale
Mean Change in Health Assessment Questionnaire - Disability Index (HAQ-DI) Responses up to 12 Weeks (Part A)
units on a scale1 mg Baricitinib (LY3009104)2 mg Baricitinib (LY3009104)4 mg Baricitinib (LY3009104)8 mg Baricitinib (LY3009104)Placebo
Mean Change in Health Assessment Questionnaire - Disability Index (HAQ-DI) Responses up to 12 Weeks (Part A)-0.302 ± 0.3336-0.396 ± 0.4759-0.469 ± 0.3463-0.422 ± 0.3646-0.077 ± 0.3552
SecondaryMean Change in HAQ-DI Responses up to 64 Weeks (Part B)

HAQ-DI was a participant-reported questionnaire that consisted of 24 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the week using response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). The highest score for any question in a category was the score of that category unless special aids or devices or help from another person was required. Answers for at least 6 of the 8 domains were required. Otherwise, HAQ-DI score was considered missing. The HAQ-DI score was the sum of the category scores divided by the number of categories scored, with a possible scores range from 0 to 3, 0 being without any difficulty and 3 being unable to do.

Time frame:
Baseline, 64 weeks
Reported as:
Mean · units on a scale
Mean Change in HAQ-DI Responses up to 64 Weeks (Part B)
units on a scaleCombined 4 mg Baricitinib (LY3009104)Combined 8 mg Baricitinib (LY3009104)
Mean Change in HAQ-DI Responses up to 64 Weeks (Part B)-0.498 ± 0.4779-0.568 ± 0.6203
SecondaryMean Value of ACR-N Response (Part A)

The ACR-N Response Index is a continuous measure of clinical, laboratory, and functional measures in RA to characterize the percentage of improvement from baseline in RA disease activity. This index is defined as the lowest of either: a) percent change in TJC, b) percent change in SJC, or c) median percent change of the remaining 5 ACR core criteria (HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, or PhGA-VAS). A participant with an ACR-N of "X" has improvement of at least "X%" in tender and swollen joints and a median improvement of at least "X%" in the 5 remaining ACR core criteria. Since ACR-N is a continuous measure, the mean values are reported instead of the originally registered percentage of participants.

Time frame:
Baseline up to 12 weeks
Reported as:
Mean · percentage of responders
Mean Value of ACR-N Response (Part A)
percentage of responders1 mg Baricitinib (LY3009104)2 mg Baricitinib (LY3009104)4 mg Baricitinib (LY3009104)8 mg Baricitinib (LY3009104)Placebo
Mean Value of ACR-N Response (Part A)28.76 ± 38.6542.48 ± 39.5245.17 ± 33.7525.58 ± 130.02-9.98 ± 58.10
SecondaryMean Value of ACR-N Response (Part B)

The ACR-N Response Index is a continuous measure of clinical, laboratory, and functional measures in RA to characterize the percentage of improvement from baseline in RA disease activity. This index is defined as the lowest of either: a) percent change in TJC, b) percent change in SJC, or c) median percent change of the remaining 5 ACR core criteria (HAQ-DI, CRP, PAAP-VAS, PtGADA-VAS, or PhGA-VAS). A participant with an ACR-N of "X" has improvement of at least "X%" in tender and swollen joints and a median improvement of at least "X%" in the 5 remaining ACR core criteria. Since ACR-N is a continuous measure, the mean values are reported instead of the originally registered percentage of participants.

Time frame:
Baseline up to 64 weeks
Reported as:
Mean · percentage of responders
Mean Value of ACR-N Response (Part B)
percentage of respondersCombined 4 mg Baricitinib (LY3009104)Combined 8 mg Baricitinib (LY3009104)
Mean Value of ACR-N Response (Part B)61.14 ± 30.7061.07 ± 33.22
SecondaryPercentage of Participants Who Achieved a DAS28 Remission at 12 Weeks (Part A)

DAS modified included the DAS28 that consisted of a composite score of the following variables: TJC28, SJC28, CRP (mg/L), and PtGADA on a 0 to 100 mm VAS: 0 mm (no arthritis activity) to 100 mm (extremely active arthritis). DAS28 calculated as: DAS28-CRP = 0.56(square root of TJC28)+0.28(square root of SJC28)+0.36\[ln(CRP +1)\]+0.014(VAS)+0.96. For remission, DAS28 is \<2.6. Percentage of participants = (number of participants with DAS28 remission) / (number of participants treated) \* 100.

Time frame:
Baseline up to 12 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a DAS28 Remission at 12 Weeks (Part A)
percentage of participants1 mg Baricitinib (LY3009104)2 mg Baricitinib (LY3009104)4 mg Baricitinib (LY3009104)8 mg Baricitinib (LY3009104)Placebo
Percentage of Participants Who Achieved a DAS28 Remission at 12 Weeks (Part A)3333425022
SecondaryPercentage of Participants Who Achieved a DAS28 Remission at 64 Weeks (Part B)

DAS modified included the DAS28 that consisted of a composite score of the following variables: TJC28, SJC28, CRP (mg/L), and PtGADA-VAS on a 0 to 100 mm VAS: 0 mm (no arthritis activity) to 100 mm (extremely active arthritis). DAS28 calculated as: DAS28-CRP = 0.56(sqrt of TJC28)+0.28(sqrt of SJC28)+0.36\[ln(CRP +1)\]+0.014(VAS)+0.96. For remission, DAS28 is \<2.6. Percentage of participants = (number of participants with DAS 28 remission) / (number of participants treated) \* 100.

Time frame:
Baseline up to 64 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a DAS28 Remission at 64 Weeks (Part B)
percentage of participantsCombined 4 mg Baricitinib (LY3009104)Combined 8 mg Baricitinib (LY3009104)
Percentage of Participants Who Achieved a DAS28 Remission at 64 Weeks (Part B)6666
SecondaryPercentage of Participants Who Achieved an SDAI Remission at 12 Weeks (Part A)

The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, PtGADA, PhGA and CRP. The equation used to calculate the SDAI: SDAI=SJC28+TJC28+PtGADA-VAS+PhGA-VAS+CRP where PtGADA-VAS=PtGADA -VAS/ 10 and PhGA-VAS=PhGA-VAS / 10. Definition of remission is SDAI ≤ 3.3. Percentage of participants = (number of responders) / (number of participants treated) \* 100

Time frame:
Baseline up to 12 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an SDAI Remission at 12 Weeks (Part A)
percentage of participants1 mg Baricitinib (LY3009104)2 mg Baricitinib (LY3009104)4 mg Baricitinib (LY3009104)8 mg Baricitinib (LY3009104)Placebo
Percentage of Participants Who Achieved an SDAI Remission at 12 Weeks (Part A)42917178
SecondaryPercentage of Participants Who Achieved an SDAI Remission at 64 Weeks (Part B)

The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, PtGADA, PhGA, and CRP. The equation used to calculate the SDAI: SDAI=SJC28+TJC28+PtGADA-VAS+PhGA-VAS+CRP where PtGADA-VAS=PtGADA-VAS / 10 and PhGA-VAS=PhGA-VAS / 10. Definition of remission is SDAI ≤ 3.3. Percentage of participants = (number of responders) / (number of participants treated) \* 100

Time frame:
Baseline up to 64 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an SDAI Remission at 64 Weeks (Part B)
percentage of participantsCombined 4 mg Baricitinib (LY3009104)Combined 8 mg Baricitinib (LY3009104)
Percentage of Participants Who Achieved an SDAI Remission at 64 Weeks (Part B)3939
SecondaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve at a Dosing Interval at Steady State (AUCtau,ss) of LY3009104

Steady state is achieved when the rate of drug input is equal to the rate of drug elimination. The AUC(tau,ss) at 1 dosing interval is the average concentration of the drug at steady state multiplied by the time of the dosing interval.

Time frame:
Weeks (Wks) 0, 8, 12, or 20: Predose, 15 to 30 minutes and 1 to 3 hours postdose; Wks 2 or 4 and 15 or 16: Predose; Wks 28, 40, 52, or 64: random single sample.
Reported as:
Geometric mean · nanomoles*hour (nM*h)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve at a Dosing Interval at Steady State (AUCtau,ss) of LY3009104
nanomoles*hour (nM*h)1 mg Baricitinib (LY3009104)2 mg Baricitinib (LY3009104)4 mg Baricitinib (LY3009104)8 mg Baricitinib (LY3009104)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve at a Dosing Interval at Steady State (AUCtau,ss) of LY3009104237 ± 28.8525 ± 211020 ± 32.51900 ± 24.1
SecondaryPK: Maximum Concentration at Steady State of Dosing (Cmax,ss) of LY3009104
Time frame:
Wks 0, 8, 12, or 20: Predose, 15 to 30 minutes and 1 to 3 hours postdose; Wks 2 or 4 and 15 or 16: Predose; Wks 28, 40, 52, or 64: random single sample.
Reported as:
Geometric mean · nM
PK: Maximum Concentration at Steady State of Dosing (Cmax,ss) of LY3009104
nM1 mg Baricitinib (LY3009104)2 mg Baricitinib (LY3009104)4 mg Baricitinib (LY3009104)8 mg Baricitinib (LY3009104)
PK: Maximum Concentration at Steady State of Dosing (Cmax,ss) of LY300910435.7 ± 20.973.5 ± 22.5147 ± 20.6278 ± 21.7

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1/49 (2%)26/49 (53.1%)
1 mg Baricitinib (LY3009104)—0/24 (0%)11/24 (45.8%)
2 mg Baricitinib (LY3009104)—1/24 (4.2%)12/24 (50%)
4 mg Baricitinib (LY3009104)—0/24 (0%)13/24 (54.2%)
8 mg Baricitinib (LY3009104)—1/24 (4.2%)17/24 (70.8%)
Placebo / 4 mg Baricitinib (LY3009104)—1/24 (4.2%)21/24 (87.5%)
1 mg Baricitinib (LY3009104) / 4mg Baricitinib (LY3009104)—1/12 (8.3%)11/12 (91.7%)
2 mg Baricitinib (LY3009104) / 4 mg Baricitinib (LY3009104)—3/12 (25%)11/12 (91.7%)
4 mg Baricitinib (LY3009104) / 4 mg Baricitinib (LY3009104)—3/23 (13%)22/23 (95.7%)
Placebo /8 mg Baricitinib (LY3009104)—2/23 (8.7%)23/23 (100%)
1 mg Baricitinib (LY3009104) / 8 mg Baricitinib (LY3009104)—2/11 (18.2%)11/11 (100%)
2 mg Baricitinib (LY3009104) / 8 mg Baricitinib (LY3009104)—2/12 (16.7%)12/12 (100%)
8 mg Baricitinib (LY3009104) / 8 mg Baricitinib (LY3009104)—6/24 (25%)23/24 (95.8%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventPlacebo1 mg Baricitinib (LY3009104)2 mg Baricitinib (LY3009104)4 mg Baricitinib (LY3009104)8 mg Baricitinib (LY3009104)Placebo / 4 mg Baricitinib (LY3009104)1 mg Baricitinib (LY3009104) / 4mg Baricitinib (LY3009104)2 mg Baricitinib (LY3009104) / 4 mg Baricitinib (LY3009104)4 mg Baricitinib (LY3009104) / 4 mg Baricitinib (LY3009104)Placebo /8 mg Baricitinib (LY3009104)1 mg Baricitinib (LY3009104) / 8 mg Baricitinib (LY3009104)2 mg Baricitinib (LY3009104) / 8 mg Baricitinib (LY3009104)8 mg Baricitinib (LY3009104) / 8 mg Baricitinib (LY3009104)
Herpes zosterInfections and infestations0/490/240/240/240/240/240/121/120/230/231/110/121/24
FallInjury, poisoning and procedural complications0/490/240/240/240/240/240/121/120/231/231/110/120/24
Ulna fractureInjury, poisoning and procedural complications0/490/240/240/240/240/240/120/120/230/231/110/120/24
Blood creatine phosphokinase increasedInvestigations0/490/240/240/240/240/240/120/120/230/231/110/120/24
Cerebral haemorrhageNervous system disorders0/490/240/240/240/240/240/120/120/230/231/110/120/24
CataractEye disorders0/490/240/240/241/240/240/120/120/230/230/111/121/24
Large intestine polypGastrointestinal disorders0/490/240/240/240/240/240/121/120/230/230/110/121/24
Pancreatitis acuteGastrointestinal disorders0/490/241/240/240/240/240/121/120/230/230/110/120/24
Pneumocystis jirovecii pneumoniaInfections and infestations0/490/240/240/240/241/240/120/120/230/230/111/120/24
PneumoniaInfections and infestations0/490/240/240/240/240/241/120/120/230/230/110/120/24
Most frequent other events
Showing 10 of 228
Most frequent other events
EventPlacebo1 mg Baricitinib (LY3009104)2 mg Baricitinib (LY3009104)4 mg Baricitinib (LY3009104)8 mg Baricitinib (LY3009104)Placebo / 4 mg Baricitinib (LY3009104)1 mg Baricitinib (LY3009104) / 4mg Baricitinib (LY3009104)2 mg Baricitinib (LY3009104) / 4 mg Baricitinib (LY3009104)4 mg Baricitinib (LY3009104) / 4 mg Baricitinib (LY3009104)Placebo /8 mg Baricitinib (LY3009104)1 mg Baricitinib (LY3009104) / 8 mg Baricitinib (LY3009104)2 mg Baricitinib (LY3009104) / 8 mg Baricitinib (LY3009104)8 mg Baricitinib (LY3009104) / 8 mg Baricitinib (LY3009104)
NasopharyngitisInfections and infestations6/492/242/242/242/244/245/126/127/239/231/111/125/24
Dental cariesGastrointestinal disorders0/490/240/240/240/240/240/120/121/230/232/110/120/24
Blood creatine phosphokinase increasedInvestigations2/490/240/242/243/244/241/120/123/234/232/112/122/24
HyperlipidaemiaMetabolism and nutrition disorders1/491/241/240/241/241/241/120/121/233/232/111/123/24
Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders0/490/240/240/241/240/241/120/121/231/232/111/120/24
ConstipationGastrointestinal disorders1/490/240/240/240/242/242/121/120/232/231/111/121/24
NauseaGastrointestinal disorders0/490/240/242/240/241/240/120/120/230/231/112/120/24
Hepatic function abnormalHepatobiliary disorders0/490/243/240/243/241/242/121/123/230/230/110/122/24
Herpes zosterInfections and infestations0/490/240/240/240/240/241/122/121/231/231/110/122/24
LacerationInjury, poisoning and procedural complications0/490/240/240/240/240/240/122/120/230/230/110/120/24

Baseline characteristics

All randomized participants who received any amount of study treatment. All participants who completed Part A were re-randomized to 4 mg or 8 mg in Part B.

Age, Continuous
Age, Continuous(years)Part A: 1 mg Baricitinib (LY3009104)Part A: 2 mg Baricitinib (LY3009104)Part A: 4 mg Baricitinib (LY3009104)Part A: 8 mg Baricitinib (LY3009104)Part A: PlaceboTotal
Mean52.7 ± 12.856.1 ± 11.557.5 ± 10.453.6 ± 11.351.1 ± 12.053.6 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)Part A: 1 mg Baricitinib (LY3009104)Part A: 2 mg Baricitinib (LY3009104)Part A: 4 mg Baricitinib (LY3009104)Part A: 8 mg Baricitinib (LY3009104)Part A: PlaceboTotal
Female2221191739118
Male23571027
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A: 1 mg Baricitinib (LY3009104)Part A: 2 mg Baricitinib (LY3009104)Part A: 4 mg Baricitinib (LY3009104)Part A: 8 mg Baricitinib (LY3009104)Part A: PlaceboTotal
Hispanic or Latino000000
Not Hispanic or Latino2424242449145
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A: 1 mg Baricitinib (LY3009104)Part A: 2 mg Baricitinib (LY3009104)Part A: 4 mg Baricitinib (LY3009104)Part A: 8 mg Baricitinib (LY3009104)Part A: PlaceboTotal
American Indian or Alaska Native000000
Asian2424242449145
Native Hawaiian or Other Pacific Islander000000
Black or African American000000
White000000
More than one race000000
Unknown or Not Reported000000
Region of Enrollment
Region of Enrollment(Participants)Part A: 1 mg Baricitinib (LY3009104)Part A: 2 mg Baricitinib (LY3009104)Part A: 4 mg Baricitinib (LY3009104)Part A: 8 mg Baricitinib (LY3009104)Part A: PlaceboTotal
Japan2424242449145
08

Study locations

14 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chiba, 260-8712, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fukuoka, 812-0025, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hiroshima, 730-0017, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hokkaido, 063-0811, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hyogo, 673-1462, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ibaragi, 316-0035, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kagoshima, 890-0067, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kanagawa, 252-0392, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nagasaki, 857-1165, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Oita, 870-0823, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Okayama, 700-8607, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Osaka, 586-8521, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tokyo, 130-0013, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Toyama, 933-0874, Japan
09

References and documents

Publications

  • Taylor PC, Takeuchi T, Burmester GR, Durez P, Smolen JS, Deberdt W, Issa M, Terres JR, Bello N, Winthrop KL. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Ann Rheum Dis. 2022 Mar;81(3):335-343. doi: 10.1136/annrheumdis-2021-221276. Epub 2021 Oct 27. PubMed 34706874 ↗
  • Combe B, Balsa A, Sarzi-Puttini P, Tony HP, de la Torre I, Rogai V, Durand F, Witt S, Zhong J, Dougados M. Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib. Ann Rheum Dis. 2019 Aug;78(8):1135-1138. doi: 10.1136/annrheumdis-2018-214261. Epub 2019 Mar 6. No abstract available. PubMed 30842122 ↗
  • Taylor PC, Kremer JM, Emery P, Zuckerman SH, Ruotolo G, Zhong J, Chen L, Witt S, Saifan C, Kurzawa M, Otvos JD, Connelly MA, Macias WL, Schlichting DE, Rooney TP, de Bono S, McInnes IB. Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies. Ann Rheum Dis. 2018 Jul;77(7):988-995. doi: 10.1136/annrheumdis-2017-212461. Epub 2018 Feb 20. PubMed 29463520 ↗
  • Tanaka Y, Ishii T, Cai Z, Schlichting D, Rooney T, Macias W. Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: A 52-week, randomized, single-blind, extension study. Mod Rheumatol. 2018 Jan;28(1):20-29. doi: 10.1080/14397595.2017.1307899. Epub 2017 Apr 25. PubMed 28440680 ↗
  • Tanaka Y, Emoto K, Cai Z, Aoki T, Schlichting D, Rooney T, Macias W. Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study. J Rheumatol. 2016 Mar;43(3):504-11. doi: 10.3899/jrheum.150613. Epub 2016 Feb 1. Erratum In: J Rheumatol. 2016 May;43(5):998. doi: 10.3899/jrheum.150613.C1. PubMed 26834213 ↗

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Nov 2012 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2018, 6 years after primary completion. A results delay was requested in Jan 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2011
First posted
Nov 10, 2011
Start
Nov 2011
Primary completionActual
Nov 2012
CompletionActual
Dec 2013
Results delay requested
Jan 11, 2013
Results first posted
Nov 1, 2018
Last update
Sep 20, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01469013
Responsible party
Sponsor
First posted
Nov 10, 2011
Start date
Nov 2011
Primary completion
Nov 2012
Completion
Dec 2013
Results posted
Nov 1, 2018
Last update
Sep 20, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion